Annual Total Expenses
$14.58 M
-$5.21 M-26.32%
December 31, 2023
Summary
- As of February 26, 2025, MRKR annual total expenses is $14.58 million, with the most recent change of -$5.21 million (-26.32%) on December 31, 2023.
- During the last 3 years, MRKR annual total expenses has fallen by -$14.30 million (-49.52%).
- MRKR annual total expenses is now -90.16% below its all-time high of $148.17 million, reached on December 31, 2018.
Performance
MRKR Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$2.40 M
+$91.80 K+3.98%
September 30, 2024
Summary
- As of February 26, 2025, MRKR quarterly total expenses is $2.40 million, with the most recent change of +$91.80 thousand (+3.98%) on September 30, 2024.
- Over the past year, MRKR quarterly total expenses has increased by +$91.80 thousand (+3.98%).
- MRKR quarterly total expenses is now -98.23% below its all-time high of $135.87 million, reached on December 31, 2018.
Performance
MRKR Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
MRKR Total Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -26.3% | +4.0% |
3 y3 years | -49.5% | +4.0% |
5 y5 years | -90.2% | -62.3% |
MRKR Total Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -63.1% | at low | -75.5% | +4.0% |
5 y | 5-year | -63.1% | at low | -78.0% | +4.0% |
alltime | all time | -90.2% | +3738.2% | -98.2% | +457.9% |
Marker Therapeutics Total Expenses History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $2.40 M(+4.0%) |
Jun 2024 | - | $2.31 M(-9.5%) |
Mar 2024 | - | $2.55 M(-13.2%) |
Dec 2023 | $14.58 M(-26.3%) | $2.94 M(-8.2%) |
Sep 2023 | - | $3.20 M(-22.6%) |
Jun 2023 | - | $4.13 M(-4.1%) |
Mar 2023 | - | $4.31 M(+41.8%) |
Dec 2022 | $19.79 M(-49.9%) | $3.04 M(-47.8%) |
Sep 2022 | - | $5.83 M(+10.6%) |
Jun 2022 | - | $5.27 M(-46.2%) |
Mar 2022 | - | $9.79 M(+0.3%) |
Dec 2021 | $39.48 M(+36.7%) | $9.76 M(-2.6%) |
Sep 2021 | - | $10.02 M(-8.1%) |
Jun 2021 | - | $10.91 M(+24.2%) |
Mar 2021 | - | $8.78 M(+3.2%) |
Dec 2020 | $28.89 M(+28.2%) | $8.51 M(+15.4%) |
Sep 2020 | - | $7.38 M(+16.0%) |
Jun 2020 | - | $6.36 M(-4.3%) |
Mar 2020 | - | $6.64 M(+23.9%) |
Dec 2019 | $22.53 M(-84.8%) | $5.36 M(-5.2%) |
Sep 2019 | - | $5.65 M(-3.7%) |
Jun 2019 | - | $5.87 M(+4.2%) |
Mar 2019 | - | $5.64 M(-95.9%) |
Dec 2018 | $148.17 M(+1190.7%) | $135.87 M(+2968.2%) |
Sep 2018 | - | $4.43 M(-5.3%) |
Jun 2018 | - | $4.67 M(+46.2%) |
Mar 2018 | - | $3.20 M(+19.3%) |
Dec 2017 | $11.48 M(+39.0%) | $2.68 M(-32.8%) |
Sep 2017 | - | $3.99 M(+66.7%) |
Jun 2017 | - | $2.39 M(-1.0%) |
Mar 2017 | - | $2.42 M(+51.9%) |
Dec 2016 | $8.26 M(+34.1%) | $1.59 M(-41.5%) |
Sep 2016 | - | $2.72 M(+24.0%) |
Jun 2016 | - | $2.19 M(+25.1%) |
Mar 2016 | - | $1.75 M(-22.2%) |
Dec 2015 | $6.16 M(+82.7%) | $2.25 M(+29.7%) |
Sep 2015 | - | $1.74 M(+52.7%) |
Jun 2015 | - | $1.14 M(+10.7%) |
Mar 2015 | - | $1.03 M(+160.8%) |
Dec 2014 | $3.37 M(+26.5%) | $394.20 K(-71.5%) |
Sep 2014 | - | $1.38 M(+170.8%) |
Jun 2014 | - | $510.90 K(-56.9%) |
Mar 2014 | - | $1.19 M(-1.9%) |
Dec 2013 | $2.66 M(-51.4%) | $1.21 M(+316.8%) |
Sep 2013 | - | $290.30 K(-24.4%) |
Jun 2013 | - | $383.90 K(-50.8%) |
Mar 2013 | - | $780.20 K(-39.4%) |
Dec 2012 | $5.48 M | $1.29 M(+121.3%) |
Sep 2012 | - | $581.90 K(-80.8%) |
Jun 2012 | - | $3.04 M(+428.3%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2012 | - | $575.10 K(+17.7%) |
Dec 2011 | $2.64 M(-37.7%) | $488.70 K(-39.0%) |
Sep 2011 | - | $801.20 K(+32.8%) |
Jun 2011 | - | $603.30 K(-18.9%) |
Mar 2011 | - | $743.60 K(-15.4%) |
Dec 2010 | $4.23 M(+0.9%) | $879.10 K(+13.4%) |
Sep 2010 | - | $775.30 K(-30.3%) |
Jun 2010 | - | $1.11 M(-24.0%) |
Mar 2010 | - | $1.46 M(-52.5%) |
Dec 2009 | $4.19 M(+179.5%) | $3.08 M(+619.5%) |
Sep 2009 | - | $428.30 K(+7.9%) |
Jun 2009 | - | $396.90 K(+38.6%) |
Mar 2009 | - | $286.40 K(-79.1%) |
Dec 2008 | $1.50 M(-40.3%) | $1.37 M(+26.0%) |
Sep 2008 | - | $1.09 M(+13.9%) |
Jun 2008 | - | $953.00 K(+106.1%) |
Mar 2008 | - | $462.30 K(-47.5%) |
Dec 2007 | $2.51 M(+182.7%) | $880.70 K(+75.3%) |
Sep 2007 | - | $502.40 K(-40.5%) |
Jun 2007 | - | $845.00 K(+198.3%) |
Mar 2007 | - | $283.30 K(+3.4%) |
Dec 2006 | $888.20 K(+1.8%) | $273.90 K(-17.1%) |
Sep 2006 | - | $330.20 K(+103.6%) |
Jun 2006 | - | $162.20 K(+33.1%) |
Mar 2006 | - | $121.90 K(-274.9%) |
Dec 2005 | $872.70 K(-66.3%) | -$69.70 K(-122.3%) |
Sep 2005 | - | $312.40 K(-32.0%) |
Jun 2005 | - | $459.70 K(+174.4%) |
Mar 2005 | - | $167.50 K(-83.3%) |
Dec 2004 | $2.59 M(-55.2%) | $1.00 M(+150.5%) |
Sep 2004 | - | $399.40 K(-23.4%) |
Jun 2004 | - | $521.30 K(-22.2%) |
Mar 2004 | - | $669.70 K(-74.5%) |
Dec 2003 | $5.78 M(+152.9%) | $2.63 M(+164.9%) |
Sep 2003 | - | $993.10 K(-22.4%) |
Jun 2003 | - | $1.28 M(+46.4%) |
Mar 2003 | - | $874.60 K(-23.5%) |
Dec 2002 | $2.28 M(+501.4%) | $1.14 M(+109.2%) |
Sep 2002 | - | $546.60 K(-44.9%) |
Jun 2002 | - | $992.30 K(+326.4%) |
Mar 2002 | - | $232.70 K(+487.6%) |
Dec 2001 | $379.90 K(-22.8%) | $39.60 K(-30.2%) |
Sep 2001 | - | $56.70 K(+397.4%) |
Jun 2001 | - | $11.40 K(-95.8%) |
Mar 2001 | - | $272.10 K(-140.6%) |
Dec 2000 | $492.30 K(-58.5%) | -$670.50 K(-243.8%) |
Sep 2000 | - | $466.20 K(+580.6%) |
Jun 2000 | - | $68.50 K(-77.6%) |
Mar 2000 | - | $305.40 K |
Dec 1999 | $1.19 M | - |
FAQ
- What is Marker Therapeutics annual total expenses?
- What is the all time high annual total expenses for Marker Therapeutics?
- What is Marker Therapeutics annual total expenses year-on-year change?
- What is Marker Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Marker Therapeutics?
- What is Marker Therapeutics quarterly total expenses year-on-year change?
What is Marker Therapeutics annual total expenses?
The current annual total expenses of MRKR is $14.58 M
What is the all time high annual total expenses for Marker Therapeutics?
Marker Therapeutics all-time high annual total expenses is $148.17 M
What is Marker Therapeutics annual total expenses year-on-year change?
Over the past year, MRKR annual total expenses has changed by -$5.21 M (-26.32%)
What is Marker Therapeutics quarterly total expenses?
The current quarterly total expenses of MRKR is $2.40 M
What is the all time high quarterly total expenses for Marker Therapeutics?
Marker Therapeutics all-time high quarterly total expenses is $135.87 M
What is Marker Therapeutics quarterly total expenses year-on-year change?
Over the past year, MRKR quarterly total expenses has changed by +$91.80 K (+3.98%)